Intranasal Semax reduced movement problems and anxiety in rats whose dopamine systems were damaged by a Parkinson's-mimicking neurotoxin.
0.2 mg/kg daily intranasalThis low dose of Semax delivered through the nose was sufficient to reduce the severity of dopaminergic damage caused by the Parkinson's-mimicking neurotoxin MPTP
What the researchers found
Daily intranasal administration of Semax (an ACTH(4-10) analog peptide, sequence MEHFPGP) at 0.2 mg/kg reduced the severity of behavioral disturbances caused by the neurotoxin MPTP in rats. MPTP selectively destroys dopamine neurons — the same neurons lost in Parkinson's disease — causing decreased movement and increased anxiety. Semax treatment lessened both of these deficits.
The researchers proposed two mechanisms for Semax's protective effects: direct modulation of the dopaminergic system and broader neurotrophic (nerve-supporting) activity of the peptide.
Why it matters
Parkinson's disease is caused by the progressive loss of dopamine-producing neurons, and there are currently no treatments that slow this process. Semax is a synthetic peptide developed in Russia that has shown neuroprotective properties in various models. This study suggests it may specifically protect the dopaminergic system — the exact pathway that fails in Parkinson's — though much more research would be needed to translate this to human treatment.
The numbers in context
MPTP dose: 25 mg/kg single i.p. injection · Semax dose: 0.2 mg/kg daily intranasal · Reduced movement deficits · Reduced anxiety behaviors
How the study worked
Animal study in white rats. MPTP neurotoxin was administered as a single intraperitoneal injection at 25 mg/kg to create dopaminergic system lesions (a standard Parkinson's disease model). Semax was given daily via intranasal administration at 0.2 mg/kg. Behavioral outcomes including movement activity and anxiety were assessed.
Who was studied
White rats with MPTP-induced dopaminergic brain lesions
What this study cannot tell us
Rat study with limited translational certainty to human Parkinson's disease. The MPTP model produces acute dopaminergic damage rather than the progressive neurodegeneration seen in actual Parkinson's. Small study with no specified sample size in the abstract. Published in 2004 with no subsequent large-scale follow-up on this specific application. Semax is primarily used in Russia and not widely studied in Western clinical settings.
How to read the evidence
This is a preliminary-grade animal study using a standard but imperfect Parkinson's disease model. The MPTP rat model produces acute damage rather than progressive degeneration, and the study has not been replicated at scale or in human trials.
When this study was published
Published in 2004, this is an older study from the Russian neuropeptide research tradition. While Semax has been used clinically in Russia for decades, this specific Parkinson's application has not been pursued in large-scale Western clinical trials.
The bigger picture
Semax has been approved in Russia for stroke and cognitive enhancement but remains largely unknown in Western medicine. This study adds to evidence that it may have neuroprotective properties specifically relevant to dopaminergic neurodegeneration. With growing interest in peptide-based neuroprotection and intranasal brain delivery, Semax's mechanism in dopamine protection deserves further investigation with modern techniques.
Questions still open
- Could Semax slow dopamine neuron loss in human Parkinson's disease if given early enough in the disease process?
- Does Semax's neuroprotective effect work by preventing neuron death, promoting neuron repair, or both?
- Why hasn't Semax been studied in larger, Western-standard clinical trials for neurodegenerative conditions?
Common questions
What is Semax and where is it used?
Could Semax treat Parkinson's disease?
Read the original research
The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.
Neuroscience and behavioral physiology, 34(4), 399-405
Citation
Levitskaya, N G; Sebentsova, E A; Andreeva, L A; Alfeeva, L Yu; Kamenskii, A A; Myasoedov, N F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.. Neuroscience and behavioral physiology, 34(4), 399-405.